Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome.
作者信息
Coutsouvelis John, Wiseman Meredith, Hui Lisa, Poole Susan, Dooley Michael, Patil Sushrut, Avery Sharon, Wei Andrew, Spencer Andrew
出版信息
Br J Clin Pharmacol. 2013 Feb;75(2):550-3. doi: 10.1111/j.1365-2125.2012.04355.x.
Abstract
摘要
相似文献
1
Effectiveness of a single fixed dose of rasburicase 3 mg in the management of tumour lysis syndrome.单次固定剂量3毫克拉布立酶治疗肿瘤溶解综合征的疗效
Br J Clin Pharmacol. 2013 Feb;75(2):550-3. doi: 10.1111/j.1365-2125.2012.04355.x.
2
Rasburicase in the prevention and treatment of tumour lysis syndrome.拉布立酶在肿瘤溶解综合征的预防和治疗中的应用
Intensive Crit Care Nurs. 2008 Feb;24(1):59-62. doi: 10.1016/j.iccn.2007.06.002. Epub 2007 Aug 14.
3
Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.重组尿酸氧化酶与肿瘤溶解综合征：降低剂量、适应证考量及水化治疗
J Clin Oncol. 2011 Jan 20;29(3):e67-8; author reply e69. doi: 10.1200/JCO.2010.32.6751. Epub 2010 Dec 13.
4
Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.固定剂量 6 毫克拉布立酶治疗高危癌症患者的高尿酸血症和肿瘤溶解综合征。
Ann Pharmacother. 2010 Oct;44(10):1529-37. doi: 10.1345/aph.1P296. Epub 2010 Sep 14.
5
Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.比较研究瑞昔布司他单剂量固定方案与体重剂量方案在肿瘤溶解综合征中的应用。
Pharmacotherapy. 2013 Mar;33(3):295-303. doi: 10.1002/phar.1198.
6
Single 6-mg dose of rasburicase: The experience in a large academic medical center.单次6毫克剂量的拉布立酶：大型学术医学中心的经验
J Oncol Pharm Pract. 2019 Sep;25(6):1349-1356. doi: 10.1177/1078155218791333. Epub 2018 Aug 15.
7
Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.单剂量6毫克重组尿酸氧化酶用于成人肿瘤溶解综合征的治疗
Pharmacotherapy. 2006 Jun;26(6):806-12. doi: 10.1592/phco.26.6.806.
8
Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices.在社区肿瘤学实践网络中，针对肿瘤溶解综合征管理的 rasburicase 剂量优化。
J Oncol Pharm Pract. 2024 Jul;30(5):867-872. doi: 10.1177/10781552231190005. Epub 2023 Aug 10.
9
More to rasburicase than uric Acid.
Pharmacotherapy. 2013 Sep;33(9):e177. doi: 10.1002/phar.1315. Epub 2013 Jun 6.
10
Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.单剂量拉布立酶治疗成人肿瘤溶解综合征：基于体重的方法。
J Clin Pharm Ther. 2009 Apr;34(2):207-13. doi: 10.1111/j.1365-2710.2008.00994.x.
引用本文的文献
1
Effectiveness of a Single Fixed Dose of 3 mg Rasburicase for the Prevention and Management of Hyperuricemia in Tumor Lysis Syndrome in Adults With Cancer.单次固定剂量3毫克拉布立酶预防和治疗成年癌症患者肿瘤溶解综合征中高尿酸血症的有效性。
Cureus. 2024 Sep 4;16(9):e68664. doi: 10.7759/cureus.68664. eCollection 2024 Sep.
2
Tumour lysis syndrome.肿瘤溶解综合征。
Nat Rev Dis Primers. 2024 Aug 22;10(1):58. doi: 10.1038/s41572-024-00542-w.
3
Evaluation of Rasburicase Use in the Fraser Health Authority: A Retrospective Review.弗雷泽卫生局中拉布立酶使用情况的评估：一项回顾性研究。
Can J Hosp Pharm. 2019 Jul-Aug;72(4):311-319. Epub 2018 Aug 31.
4
Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.单剂量拉布立酶（1.5毫克）预防和治疗实验室肿瘤溶解综合征的疗效
Indian J Hematol Blood Transfus. 2018 Oct;34(4):618-622. doi: 10.1007/s12288-018-0938-9. Epub 2018 Mar 3.
5
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.肿瘤溶解综合征的预防与治疗以及重组尿酸氧化酶的疗效与作用
Onco Targets Ther. 2017 Feb 2;10:597-605. doi: 10.2147/OTT.S103864. eCollection 2017.
6
Medical and alternative therapies in urinary tract stone disease.尿路结石疾病的医学及替代疗法。
World J Nephrol. 2015 Nov 6;4(5):492-9. doi: 10.5527/wjn.v4.i5.492.
本文引用的文献
1
Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review.单剂量固定剂量的拉布立酶治疗亚洲淋巴瘤患者肿瘤溶解综合征：病例系列及文献综述
Asia Pac J Clin Oncol. 2011 Dec;7(4):351-6. doi: 10.1111/j.1743-7563.2011.01464.x.
2
Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.重组尿酸氧化酶与肿瘤溶解综合征：降低剂量、适应证考量及水化治疗
J Clin Oncol. 2011 Jan 20;29(3):e67-8; author reply e69. doi: 10.1200/JCO.2010.32.6751. Epub 2010 Dec 13.
3
Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.比较 rasburicase 和别嘌醇治疗儿童肿瘤溶解综合征的经济学评价。
Am J Health Syst Pharm. 2010 Dec 15;67(24):2110-4. doi: 10.2146/ajhp100022.
4
Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.单剂量 3 毫克拉布立酶治疗血液恶性肿瘤患者高尿酸血症的疗效。
Bone Marrow Transplant. 2011 Jun;46(6):800-5. doi: 10.1038/bmt.2010.212. Epub 2010 Sep 6.
5
Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.尿酸氧化酶用于预防和治疗患癌儿童的肿瘤溶解综合征。
Cochrane Database Syst Rev. 2010 Jun 16(6):CD006945. doi: 10.1002/14651858.CD006945.pub2.
6
A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults.用于治疗成人肿瘤溶解综合征的单次固定剂量的拉布立酶（最大剂量6毫克）。
Eur J Haematol. 2010 Aug;85(2):177-9. doi: 10.1111/j.1600-0609.2010.01457.x. Epub 2010 Apr 12.
7
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.评估低剂量、基于体重的拉布立酶用于成年患者治疗或预防肿瘤溶解综合征的效果。
J Oncol Pharm Pract. 2011 Sep;17(3):147-54. doi: 10.1177/1078155210364180. Epub 2010 Mar 23.
8
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.恶性肿瘤成人和儿童肿瘤溶解综合征（TLS）风险评估和预防推荐：专家 TLS 小组共识。
Br J Haematol. 2010 May;149(4):578-86. doi: 10.1111/j.1365-2141.2010.08143.x. Epub 2010 Mar 16.
9
Managing tumor lysis syndrome in 2010.2010年肿瘤溶解综合征的管理
Leuk Lymphoma. 2010 Feb;51(2):179-80. doi: 10.3109/10428190903488788.
10
An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.肿瘤溶解综合征的识别、预防和治疗的综合临床方法。
Cancer Treat Rev. 2010 Apr;36(2):164-76. doi: 10.1016/j.ctrv.2009.11.001. Epub 2009 Dec 23.
Zotero 插件